Michael Oertel1, Khaled Elsayad2, Uwe Haverkamp1, Matthias Stelljes3, Hans Theodor Eich1. 1. Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany. 2. Department of Radiation Oncology, University Hospital of Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany. khaled.elsayad@uni-muenster.de. 3. Department of Internal Medicine, University Hospital of Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany.
Abstract
PURPOSE: Extramedullary leukaemic disease (EMD, synonym chloroma) is a rare solid manifestation of myeloid leukaemia for which the value of radiotherapy (RT) as a treatment strategy remains controversial. The aim of this study is to analyse the effectiveness of various RT doses for EMD in the modern treatment era. MATERIALS AND METHODS: Between January 2000 and June 2016, 20 patients with total of 45 lesions underwent RT for EMD at our institution. RESULTS: With a median radiation dose of 26 Gy (range 4-42 Gy), local remission could be achieved in 91% of patients (complete remission rate: 71%). The median duration of local control (DOLC) was 17 months (95% confidence interval [CI] 0.5-33) and the median overall survival (OS) after chloroma onset was 24 months (95% CI 11-38). No noticeable difference between high- and low-dose regimens has been observed (74% versus 68%; P = 0.5). In the multivariate analysis, only Eastern Cooperative Oncology Group (ECOG) score and bone marrow state during RT have proven to be determinant for durable local control and OS. CONCLUSIONS: Low-dose RT (≤26 Gy) achieves good local control compared to high-dose regimes. Bone marrow state during RT and ECOG score during RT may play a crucial role, influencing both DOLC and OS.
PURPOSE: Extramedullary leukaemic disease (EMD, synonym chloroma) is a rare solid manifestation of myeloid leukaemia for which the value of radiotherapy (RT) as a treatment strategy remains controversial. The aim of this study is to analyse the effectiveness of various RT doses for EMD in the modern treatment era. MATERIALS AND METHODS: Between January 2000 and June 2016, 20 patients with total of 45 lesions underwent RT for EMD at our institution. RESULTS: With a median radiation dose of 26 Gy (range 4-42 Gy), local remission could be achieved in 91% of patients (complete remission rate: 71%). The median duration of local control (DOLC) was 17 months (95% confidence interval [CI] 0.5-33) and the median overall survival (OS) after chloroma onset was 24 months (95% CI 11-38). No noticeable difference between high- and low-dose regimens has been observed (74% versus 68%; P = 0.5). In the multivariate analysis, only Eastern Cooperative Oncology Group (ECOG) score and bone marrow state during RT have proven to be determinant for durable local control and OS. CONCLUSIONS: Low-dose RT (≤26 Gy) achieves good local control compared to high-dose regimes. Bone marrow state during RT and ECOG score during RT may play a crucial role, influencing both DOLC and OS.
Authors: Sung Ho Moon; Kwan Ho Cho; Chang-Geol Lee; Ki Chang Keum; Yeon-Sil Kim; Hong-Gyun Wu; Jin Ho Kim; Yong Chan Ahn; Dongryul Oh; Jong Hoon Lee Journal: Strahlenther Onkol Date: 2016-03-14 Impact factor: 3.621
Authors: James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield Journal: Blood Date: 2009-04-08 Impact factor: 22.113
Authors: Spencer J Collis; Sara Neutzel; Travis L Thompson; Michael J Swartz; Larry E Dillehay; Michael I Collector; Saul J Sharkis; Theodore L DeWeese Journal: Radiat Res Date: 2004-07 Impact factor: 2.841
Authors: Adam J Mead; David C Linch; Robert K Hills; Keith Wheatley; Alan K Burnett; Rosemary E Gale Journal: Blood Date: 2007-04-24 Impact factor: 22.113
Authors: Khaled Elsayad; Michael Oertel; Laila König; Sebastian Hüske; Emmanuelle Le Ray; Mohamed A M Meheissen; Amr Abdelaziz Elsaid; Essam Elfaham; Jürgen Debus; Youlia Kirova; Klaus Herfarth; Hans Theodor Eich Journal: Cancers (Basel) Date: 2020-03-13 Impact factor: 6.639